Edwards Lifesciences (NYSE: EW) today announced new data demonstrating long-term benefits with its Sapien heart valve system.
Investor's Business Daily on MSN
Edwards Jumps On Beat-And-Raise, Announces CFO Transition
Edwards Lifesciences stock jumped late Thursday after the medtech company boosted its 2025 outlook after beating quarterly ...
GlobalData on MSN
Edwards solidifies TAVR dominance in long-term trial readout
The respective readouts demonstrated TAVR’s comparable performance to surgical aortic valve replacement treatment.
Edwards Lifesciences (NYSE: EW) today announced seven-year data from the PARTNER 3 trial, reaffirming the early and sustained patient benefits of Edwards TAVR. The data, which showed superior clinical ...
The results underscore the need to perform CT imaging when deciding between procedures in patients with aortic stenosis.
WASHINGTON, DC — New European registry data on transcatheter aortic-valve replacement (TAVR) in patients at lower surgical risk than those studied in the pivotal randomized trials offers the ...
Penumbra, Inc. (NYSE: PEN) announced the results of the landmark STORM-PE randomized controlled trial (RCT), which found that ...
Notícias ao Minuto on MSN
Penumbra study backs mechanical thrombectomy for treating pulmonary embolism
The study found that the use of the company’s computer-assisted vacuum thrombectomy (CAVT) system, a form of mechanical ...
SBRT is noninferior to traditional radiation for low- to intermediate-risk localized prostate cancer, offering a viable treatment alternative. The PACE-B study showed a 95.8% five-year rate of no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback